Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $182.1 million.

  • Beam Therapeutics' Total Current Liabilities rose 9.81% to $182.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.6 million, marking a year-over-year increase of 9.81%. This contributed to the annual value of $182.1 million for FY2024, which is 11.43% down from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Total Current Liabilities is $182.1 million, which was down 11.43% from $205.6 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Total Current Liabilities peaked at $223.6 million during FY2022, and registered a low of $102.3 million during FY2020.
  • Over the past 3 years, Beam Therapeutics' median Total Current Liabilities value was $205.6 million (recorded in 2023), while the average stood at $203.7 million.
  • As far as peak fluctuations go, Beam Therapeutics' Total Current Liabilities spiked by 251.21% in 2020, and later dropped by 11.43% in 2024.
  • Over the past 5 years, Beam Therapeutics' Total Current Liabilities (Yearly) stood at $102.3 million in 2020, then skyrocketed by 108.56% to $213.4 million in 2021, then increased by 4.76% to $223.6 million in 2022, then dropped by 8.06% to $205.6 million in 2023, then fell by 11.43% to $182.1 million in 2024.